Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Larkin, James; Del Vecchio, Michele; Mandalà, Mario; Gogas, Helen; Arance, Ana; Dalle, Stéphane; Lance Cowey, Charles; Schenker, Michael; Grob, Jean‐Jacques; Chiarion‐Sileni, Vanna; Márquez‐Rodas, Iván; O. Butler, Marcus; Maria Di Giacomo, Anna; R. Middleton, Mark; Lutzky, Jose; de la Cruz‐Merino, Luis; Arenberger, Petr; Atkinson, Victoria; G. Hill, Andrew; A. Fecher, Leslie; Millward, Michael; Nathan, Paul; I. Khushalani, Nikhil; Queirolo, Paola; Ritchings, Corey; Lobo, Maurice; Askelson, Margarita; Tang, Hao; Dolfi, Sonia; A. Ascierto, Paolo; S. Weber, Jeffrey

doi:10.1158/1078-0432.ccr-22-3145

Public

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Published in Clinical Cancer Research • Apr 14, 2023

Authors:

James Larkin

Michele Del Vecchio

Mario Mandalà

Abstract

PURPOSE: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB-C or stage IV melanoma, with benefit sustained at 4 years. We report updated 5-year effi...

Subject

Ipilimumab

Nivolumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!